Drug Trial Radar · NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Jun 23, 2026
Primary completion
Nov 30, 2028
Study completion Jan 31, 2033
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Participants will receive cevostamab IV as per the schedule given in the protocol.
PomalidomideDrug
Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.
DexamethasoneDrug
Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.
DaratumumabDrug
Participants will receive daratumumab SC as per the schedule given in the protocol.
ElotuzumabDrug
Participants will receive elotuzumab IV as per the schedule given in the protocol.
CarfilzomibDrug
Participants will receive carfilzomib IV as per the schedule given in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Residual Disease (MRD)-Negative Complete Response (CR) RateTime frame: Up to 1 year after the last participant is randomized
- Progression-Free Survival (PFS)Time frame: Up to 5 years after the last participant is randomized
Locations
105 sites in 18 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
City of Hope - Lennar Foundation Cancer Center
Irvine, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center MedStar Georgetown Cancer Institute
Washington D.C., District of Columbia · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
Novant Health Cancer Institute
Charlotte, North Carolina · Recruiting
Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists
Winston-Salem, North Carolina · Recruiting
TriHealth Cancer and Blood Institute
Cincinnati, Ohio · Recruiting
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Tech University Health Sciences Center
Lubbock, Texas · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Americas Centro de Oncologia Integrado
Rio de Janeiro, Brazil · Recruiting
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil · Recruiting
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, Canada · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, China · Recruiting
Qilu Hospital of Shandong University
Jinan, China · Recruiting
The First Affiliate Hospital of Guangxi Medical University
Nanning, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, China · Recruiting
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China · Recruiting
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Recruiting
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China · Recruiting
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affilliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS
Hangzhou, Zhejiang, China · Recruiting
Fakultni nemocnice Brno
Brno, Czechia · Recruiting
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia · Recruiting
Fakultni nemocnice Ostrava
Ostrava, Czechia · Recruiting
Aarhus Universitetshospital
Aarhus, Denmark · Recruiting
Rigshospitalet
København Ø, Denmark · Recruiting
Sjællands Universitetshospital, Køge;Hæmatologisk afdeling
Køge, Denmark · Recruiting
Sygehus Lillebælt, Vejle;Hæmatologisk Forskningsenhed, HKFE
Vejle, Denmark · Recruiting
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.